Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for plaque psoriasis and obesity.
The study demonstrated the efficacy of its drugs Taltz and Zepbound in treating psoriasis and obesity.
27.1% of participants receiving Taltz and Zepbound reached complete skin clearance (Psoriasis Area Severity Index (PASI) 100) and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone, meeting the primary endpoint.
Taltz and Zepbound delivered a 40% relative increase over Taltz monotherapy in the proportion of patients who achieved PASI 100 (40.6% vs.29%).
Don’t Miss:
The most common adverse events were nausea, diarrhea, constipation, injection site reaction, dosing error, vomiting, and dizziness in the Taltz and Zepbound concomitant treatment arm, and injection site reaction, dosing error, and nasopharyngitis in the Taltz monotherapy arm.
CSL Limited (OTC:CSLLY) on Wednesday entered into an exclusive licensing agreement with Eli Lilly, granting certain rights to develop and commercialize clazakizumab.
CSL will receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory, and commercial milestone payments, as well as royalties on global net sales.
CSL will retain exclusive rights to develop and commercialize clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD). CSL is advancing the ongoing POSIBIL 6ESKD Phase 3 trial of clazakizumab.
Lilly will explore the development, global regulatory approval, and commercialisation of clazakizumab in additional indications.
Trending: Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.
The stock is currently trading 2.7% below its 20-day simple moving average (SMA) and 3.2% below its 50-day SMA, indicating short-term weakness. However, it remains 4.3% above its 100-day SMA and 17.6% above its 200-day SMA, suggesting longer-term strength.
The RSI is at 48.22, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, the MACD shows a value of -5.0984, below its signal line of -3.9365, indicating bearish pressure on the stock.
